Developer of sustainable cell-free enzyme technology pursuing uses that include active ingredients for nutraceuticals and pharmaceuticals, CEO Michael Heltzen tell GEN Edge
GEN Edge: What’s in a Name - Out with Invizyne, In with eXoZymes
0:12
GEN Edge: What’s in a Name - Out with Invizyne, In with eXoZymes
Article excerpt
Article excerpt
Report excerpteXoZymes’ recent Q3 investor call was, in my view, a genuine inflection point for the...